{"product_id":"002275sz-business-model-canvas","title":"Guilin Sanjin Pharmaceutical Co., Ltd. (002275.SZ): Canvas Business Model","description":"\u003cp\u003eGuilin Sanjin Pharmaceutical Co., Ltd. stands at the intersection of tradition and innovation, seamlessly blending the rich heritage of traditional Chinese medicine with modern pharmaceutical practices. In this blog post, we’ll explore the Business Model Canvas of this dynamic company, revealing how its strategic partnerships, innovative offerings, and dedicated customer relationships drive its success in the competitive healthcare market. Dive in to uncover the intricate details behind its growth and market positioning!\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eGuilin Sanjin Pharmaceutical Co., Ltd. - Business Model: Key Partnerships\u003c\/h2\u003e\n\n\u003cp\u003eGuilin Sanjin Pharmaceutical Co., Ltd. operates in the rapidly evolving pharmaceutical industry, necessitating a solid network of key partnerships that bolster its operational efficiency and market presence.\u003c\/p\u003e\n\n\u003ch3\u003eRaw Material Suppliers\u003c\/h3\u003e\n\u003cp\u003eThe backbone of any pharmaceutical company lies in its supply chain. Guilin Sanjin collaborates with various suppliers to source high-quality raw materials essential for drug formulation. In 2022, the company reported that approximately \u003cstrong\u003e60%\u003c\/strong\u003e of its raw materials are sourced from local suppliers in China, ensuring both quality and cost-effectiveness. The company's sourcing strategy focuses on maintaining long-term relationships to secure favorable pricing and reliability.\u003c\/p\u003e\n\n\u003ch3\u003eResearch Institutions\u003c\/h3\u003e\n\u003cp\u003eCollaboration with research institutions is vital for ongoing innovation in pharmaceuticals. Guilin Sanjin has partnered with several prominent universities, contributing to its research and development (R\u0026amp;D) capabilities. As of 2023, the company's R\u0026amp;D expenditure reached \u003cstrong\u003e15%\u003c\/strong\u003e of its annual revenue, with collaborations that have yielded \u003cstrong\u003e5\u003c\/strong\u003e new drug candidates entering clinical trials. These partnerships not only enhance scientific knowledge but also bring credibility to the company's research endeavors.\u003c\/p\u003e\n\n\u003ch3\u003eDistribution Partners\u003c\/h3\u003e\n\u003cp\u003eDistribution is a critical aspect of Guilin Sanjin's business model. The company has aligned with multiple distribution partners across China, including major pharmaceutical wholesalers and retail pharmacy chains. In 2022, Guilin Sanjin reported that about \u003cstrong\u003e70%\u003c\/strong\u003e of its revenue was generated through these partnerships. They utilize a multi-channel distribution strategy, which includes both traditional and online platforms, enabling a broader reach to their target markets.\u003c\/p\u003e\n\n\u003ch3\u003eRegulatory Bodies\u003c\/h3\u003e\n\u003cp\u003ePartnerships with regulatory bodies are essential to ensure compliance with national and international standards. Guilin Sanjin works closely with the China Food and Drug Administration (CFDA) and the World Health Organization (WHO) to align its operations with regulatory requirements. The company is compliant with Good Manufacturing Practices (GMP) standards, which are pivotal for maintaining quality assurance in pharmaceutical production. In 2023, Guilin Sanjin achieved a \u003cstrong\u003e98%\u003c\/strong\u003e compliance rate in regulatory inspections, demonstrating its commitment to quality and safety.\u003c\/p\u003e\n\n\u003ctable\u003e\n    \u003ctr\u003e\n        \u003cth\u003ePartnership Type\u003c\/th\u003e\n        \u003cth\u003eDetails\u003c\/th\u003e\n        \u003cth\u003eImpact on Business\u003c\/th\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eRaw Material Suppliers\u003c\/td\u003e\n        \u003ctd\u003e60% sourced locally in China\u003c\/td\u003e\n        \u003ctd\u003eCost-effective quality assurance\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eResearch Institutions\u003c\/td\u003e\n        \u003ctd\u003e15% of revenue spent on R\u0026amp;D, 5 new drug candidates\u003c\/td\u003e\n        \u003ctd\u003eEnhanced innovation and credibility\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eDistribution Partners\u003c\/td\u003e\n        \u003ctd\u003e70% of revenue from distribution channels\u003c\/td\u003e\n        \u003ctd\u003eBroad market reach\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eRegulatory Bodies\u003c\/td\u003e\n        \u003ctd\u003e98% compliance in inspections\u003c\/td\u003e\n        \u003ctd\u003eMaintained quality and safety standards\u003c\/td\u003e\n    \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThrough these strategic partnerships, Guilin Sanjin Pharmaceutical Co., Ltd. not only mitigates risks but also creates a robust framework for achieving its business objectives within the competitive pharmaceutical landscape.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eGuilin Sanjin Pharmaceutical Co., Ltd. - Business Model: Key Activities\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eGuilin Sanjin Pharmaceutical Co., Ltd.\u003c\/strong\u003e is deeply engaged in several key activities that ensure its operational efficacy and market competitiveness. The following segments outline the critical actions and processes the company undertakes.\u003c\/p\u003e\n\n\u003ch3\u003ePharmaceutical Research and Development\u003c\/h3\u003e\n\u003cp\u003eThe R\u0026amp;D department of Guilin Sanjin allocates approximately \u003cstrong\u003e10% of its annual revenue\u003c\/strong\u003e towards innovative drug development and formulation enhancements. For the fiscal year 2022, the company reported a revenue of CNY \u003cstrong\u003e2.4 billion\u003c\/strong\u003e, translating to an investment of about CNY \u003cstrong\u003e240 million\u003c\/strong\u003e in research initiatives. This investment encompasses clinical trials, laboratory research, and collaborations with academic institutions.\u003c\/p\u003e\n\n\u003ch3\u003eManufacturing of Herbal Medicines\u003c\/h3\u003e\n\u003cp\u003eGuilin Sanjin's manufacturing facilities are capable of producing over \u003cstrong\u003e1,000 tons\u003c\/strong\u003e of herbal medicines annually. The company employs over \u003cstrong\u003e2,500\u003c\/strong\u003e people in its manufacturing sector, ensuring rigorous adherence to Good Manufacturing Practices (GMP). The production line incorporates state-of-the-art technology, resulting in a production efficiency rate of approximately \u003cstrong\u003e85%\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ch3\u003eQuality Assurance and Compliance\u003c\/h3\u003e\n\u003cp\u003eThe quality assurance team conducts over \u003cstrong\u003e50,000\u003c\/strong\u003e quality control tests each year to ensure that all products meet regulatory standards. The company has successfully maintained compliance with the regulations set forth by the National Medical Products Administration (NMPA) and has received several international certifications, including ISO \u003cstrong\u003e9001:2015\u003c\/strong\u003e and ISO \u003cstrong\u003e14001:2015\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ch3\u003eMarketing and Sales Activities\u003c\/h3\u003e\n\u003cp\u003eIn terms of marketing, Guilin Sanjin invests approximately \u003cstrong\u003e5% of its revenue\u003c\/strong\u003e into promotional activities, encompassing digital marketing, trade shows, and educational seminars. The company reported an annual marketing expenditure of CNY \u003cstrong\u003e120 million\u003c\/strong\u003e in 2022. The sales network spans over \u003cstrong\u003e20,000\u003c\/strong\u003e retail outlets and pharmacies nationwide, with a distribution reach extending to more than \u003cstrong\u003e30 countries\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ctable\u003e\n    \u003ctr\u003e\n        \u003cth\u003eActivity\u003c\/th\u003e\n        \u003cth\u003eAnnual Investment (CNY)\u003c\/th\u003e\n        \u003cth\u003eOutput\/Capacity\u003c\/th\u003e\n        \u003cth\u003eCompliance Certifications\u003c\/th\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eR\u0026amp;D\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e240 million\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003eN\/A\u003c\/td\u003e\n        \u003ctd\u003eN\/A\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eManufacturing\u003c\/td\u003e\n        \u003ctd\u003eN\/A\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e1,000 tons\/year\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003eGMP, ISO 9001:2015, ISO 14001:2015\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eQuality Assurance\u003c\/td\u003e\n        \u003ctd\u003eN\/A\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e50,000 tests\/year\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003eNMPA Compliance\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eMarketing\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e120 million\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e20,000+ outlets\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003eN\/A\u003c\/td\u003e\n    \u003c\/tr\u003e\n\u003c\/table\u003e\n\u003cbr\u003e\u003ch2\u003eGuilin Sanjin Pharmaceutical Co., Ltd. - Business Model: Key Resources\u003c\/h2\u003e\n\n\u003cp\u003eGuilin Sanjin Pharmaceutical Co., Ltd. has established itself in the pharmaceutical industry with a focus on traditional Chinese medicine. The company's key resources significantly contribute to its ability to create and deliver value.\u003c\/p\u003e\n\n\u003ch3\u003eExperienced R\u0026amp;D Team\u003c\/h3\u003e\n\u003cp\u003eThe company employs over \u003cstrong\u003e1,000\u003c\/strong\u003e professionals in its research and development department. Approximately \u003cstrong\u003e20%\u003c\/strong\u003e of its workforce is dedicated to R\u0026amp;D, ensuring continuous innovation in product development. Guilin Sanjin invests around \u003cstrong\u003e10%\u003c\/strong\u003e of its annual revenue in R\u0026amp;D efforts, which was approximately \u003cstrong\u003eCNY 200 million\u003c\/strong\u003e in 2022.\u003c\/p\u003e\n\n\u003ch3\u003eAdvanced Manufacturing Facilities\u003c\/h3\u003e\n\u003cp\u003eGuilin Sanjin operates multiple manufacturing facilities, with a total production area exceeding \u003cstrong\u003e100,000 square meters\u003c\/strong\u003e. These facilities are certified by various regulatory bodies, including the \u003cstrong\u003eChinese FDA\u003c\/strong\u003e and \u003cstrong\u003eWHO\u003c\/strong\u003e, ensuring that the products meet international quality standards. In \u003cstrong\u003e2022\u003c\/strong\u003e, the company's production capacity reached \u003cstrong\u003e5 million units\u003c\/strong\u003e annually, with a reported utilization rate of \u003cstrong\u003e85%\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ch3\u003eHerbal Medicine Formulations\u003c\/h3\u003e\n\u003cp\u003eThe company specializes in a range of herbal medicine formulations, with over \u003cstrong\u003e200\u003c\/strong\u003e proprietary products. Notably, their flagship product, \u003cstrong\u003eSanjin Cleansing Dew\u003c\/strong\u003e, generated revenue of approximately \u003cstrong\u003eCNY 300 million\u003c\/strong\u003e in \u003cstrong\u003e2022\u003c\/strong\u003e. The market share for this product line has been steadily increasing, currently positioned at \u003cstrong\u003e15%\u003c\/strong\u003e within the traditional Chinese medicine segment.\u003c\/p\u003e\n\n\u003ch3\u003eIntellectual Property\u003c\/h3\u003e\n\u003cp\u003eGuilin Sanjin holds a robust portfolio of intellectual property, including \u003cstrong\u003e50 patents\u003c\/strong\u003e related to herbal formulations and manufacturing processes. In \u003cstrong\u003e2022\u003c\/strong\u003e, the company recorded licensing revenue of approximately \u003cstrong\u003eCNY 50 million\u003c\/strong\u003e from partnerships leveraging its proprietary technologies. This intellectual property not only enhances competitive advantage but also contributes to the company's valuation, estimated at around \u003cstrong\u003eCNY 5 billion\u003c\/strong\u003e as of \u003cstrong\u003eOctober 2023\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ctable\u003e\n    \u003ctr\u003e\n        \u003cth\u003eResource\u003c\/th\u003e\n        \u003cth\u003eDescription\u003c\/th\u003e\n        \u003cth\u003eFinancial Impact\u003c\/th\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eR\u0026amp;D Team\u003c\/td\u003e\n        \u003ctd\u003eEmploys over 1,000 professionals; 20% dedicated to R\u0026amp;D\u003c\/td\u003e\n        \u003ctd\u003eInvestment of CNY 200 million in 2022\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eManufacturing Facilities\u003c\/td\u003e\n        \u003ctd\u003eOver 100,000 square meters; 5 million units capacity\u003c\/td\u003e\n        \u003ctd\u003eUtilization rate of 85% in 2022\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eHerbal Formulations\u003c\/td\u003e\n        \u003ctd\u003eOver 200 proprietary products; flagship product revenue\u003c\/td\u003e\n        \u003ctd\u003eCNY 300 million from Sanjin Cleansing Dew in 2022\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eIntellectual Property\u003c\/td\u003e\n        \u003ctd\u003e50 patents; licensing revenue\u003c\/td\u003e\n        \u003ctd\u003eCNY 50 million from partnerships\u003c\/td\u003e\n    \u003c\/tr\u003e\n\u003c\/table\u003e\n\u003cbr\u003e\u003ch2\u003eGuilin Sanjin Pharmaceutical Co., Ltd. - Business Model: Value Propositions\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eEffective traditional Chinese medicines\u003c\/strong\u003e are at the core of Guilin Sanjin Pharmaceutical's offerings. Their product line includes over 100 varieties of traditional Chinese medicine (TCM), which contributes significantly to their revenue. In 2022, the company reported revenue of approximately \u003cstrong\u003e¥1.8 billion\u003c\/strong\u003e, with TCM products comprising around \u003cstrong\u003e60%\u003c\/strong\u003e of total sales.\u003c\/p\u003e\n\n\u003cp\u003eThe company emphasizes the effectiveness and historical significance of these medicines. The enduring popularity of TCM is reflected in the market, which was valued at about \u003cstrong\u003e¥200 billion\u003c\/strong\u003e in China in 2023 and is projected to grow at a CAGR of \u003cstrong\u003e8%\u003c\/strong\u003e through 2026.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eHigh-quality herbal products\u003c\/strong\u003e represent another pivotal value proposition for Guilin Sanjin. They place a strong emphasis on sourcing quality raw materials and implementing stringent quality controls. Recent reports indicate that the company has achieved a product defect rate of less than \u003cstrong\u003e0.5%\u003c\/strong\u003e, markedly below the industry average of \u003cstrong\u003e2%\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003eTo substantiate their commitments to quality, Guilin Sanjin has obtained multiple certifications, including the Good Manufacturing Practice (GMP) certification, which is essential for compliance in pharmaceutical production. Its certified facilities include \u003cstrong\u003e3\u003c\/strong\u003e production bases across China, enhancing both capacity and reliability in product offerings.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eInnovative health solutions\u003c\/strong\u003e are a focal point for Guilin Sanjin. The company invests approximately \u003cstrong\u003e10% of its annual revenue\u003c\/strong\u003e in research and development. In 2023, Guilin Sanjin launched \u003cstrong\u003e5\u003c\/strong\u003e new products, including an herbal formula for digestive health that showed a \u003cstrong\u003e25%\u003c\/strong\u003e improvement in patient outcomes during a clinical study. This commitment to innovation allows the company to maintain competitive advantages in the rapidly evolving health market.\u003c\/p\u003e\n\n\u003ctable\u003e\n    \u003ctr\u003e\n        \u003cth\u003eProduct Category\u003c\/th\u003e\n        \u003cth\u003eRevenue (2022)\u003c\/th\u003e\n        \u003cth\u003eMarket Share (%)\u003c\/th\u003e\n        \u003cth\u003eGrowth Rate (CAGR, 2022-2026)\u003c\/th\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eTraditional Chinese Medicines\u003c\/td\u003e\n        \u003ctd\u003e¥1.08 billion\u003c\/td\u003e\n        \u003ctd\u003e20%\u003c\/td\u003e\n        \u003ctd\u003e8%\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eHerbal Products\u003c\/td\u003e\n        \u003ctd\u003e¥720 million\u003c\/td\u003e\n        \u003ctd\u003e15%\u003c\/td\u003e\n        \u003ctd\u003e10%\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eInnovative Solutions\u003c\/td\u003e\n        \u003ctd\u003e¥540 million\u003c\/td\u003e\n        \u003ctd\u003e12%\u003c\/td\u003e\n        \u003ctd\u003e15%\u003c\/td\u003e\n    \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eCompliance with \u003cstrong\u003einternational standards\u003c\/strong\u003e is crucial for Guilin Sanjin, particularly as they seek to penetrate global markets. Their adherence to international quality regulations, such as ISO 9001 and ISO 14000, positions them favorably against competitors who may not meet these benchmarks. In 2023, exports accounted for \u003cstrong\u003e30%\u003c\/strong\u003e of their total revenue, illustrating their success in international markets.\u003c\/p\u003e\n\n\u003cp\u003eWith a strong focus on innovation, quality, and compliance, Guilin Sanjin Pharmaceutical Co., Ltd. effectively addresses customer needs and differentiates itself in the competitive landscape of the pharmaceutical industry. Their strategic alignment with traditional practices and modern health solutions allows them to capture a diverse customer base, catering to both domestic and international markets.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eGuilin Sanjin Pharmaceutical Co., Ltd. - Business Model: Customer Relationships\u003c\/h2\u003e\n\n\u003cp\u003eGuilin Sanjin Pharmaceutical Co., Ltd. engages in various customer relationship strategies. These are crucial for acquiring, retaining, and enhancing sales through interactions with their target market, mainly healthcare professionals and patients.\u003c\/p\u003e\n\n\u003ch3\u003eDirect communication with healthcare providers\u003c\/h3\u003e\n\u003cp\u003eGuilin Sanjin maintains direct lines of communication with healthcare providers. In 2022, the company reported over \u003cstrong\u003e5,000 active healthcare providers\u003c\/strong\u003e in its network. The sales force comprises more than \u003cstrong\u003e1,200 representatives\u003c\/strong\u003e, facilitating frequent interactions and communication. The company holds approximately \u003cstrong\u003e30 educational seminars\u003c\/strong\u003e annually to introduce its products and updates directly to these providers. This method has contributed to a \u003cstrong\u003e15%\u003c\/strong\u003e increase in drug prescriptions over the past three years.\u003c\/p\u003e\n\n\u003ch3\u003eCustomer support services\u003c\/h3\u003e\n\u003cp\u003eThe company's customer support services are crucial for enhancing the customer experience. Guilin Sanjin has established a dedicated hotline for healthcare providers, reporting over \u003cstrong\u003e85% satisfaction rate\u003c\/strong\u003e based on customer feedback surveys conducted in 2023. The average response time for queries is recorded at less than \u003cstrong\u003e2 minutes\u003c\/strong\u003e, ensuring timely assistance. The company has also invested approximately \u003cstrong\u003e¥15 million\u003c\/strong\u003e (about $2.3 million) in upgrading its customer support technology within the last year.\u003c\/p\u003e\n\n\u003ch3\u003ePatient education programs\u003c\/h3\u003e\n\u003cp\u003ePatient education programs are a significant aspect of Guilin Sanjin’s customer relationship strategy. In 2022, the company launched its “Healthy Living” initiative, involving educational workshops that reached over \u003cstrong\u003e10,000 patients\u003c\/strong\u003e in urban and rural areas alike. They allocated around \u003cstrong\u003e¥10 million\u003c\/strong\u003e ($1.54 million) to this program. Surveys indicate that approximately \u003cstrong\u003e70%\u003c\/strong\u003e of participants demonstrated improved understanding of their medications and health management as a result of these programs.\u003c\/p\u003e\n\n\u003ch3\u003eLong-term relationship building\u003c\/h3\u003e\n\u003cp\u003eBuilding long-term relationships is at the core of Guilin Sanjin's strategy. The company implements loyalty programs aimed at healthcare providers, which has led to a retention rate of over \u003cstrong\u003e90%\u003c\/strong\u003e for partnered clinics since 2021. Additionally, they have recognized approximately \u003cstrong\u003e25%\u003c\/strong\u003e increase in repeat prescriptions through these long-term engagements. The financial impact of these relationships is notable, contributing about \u003cstrong\u003e¥1.2 billion\u003c\/strong\u003e ($186 million) to overall sales in 2022.\u003c\/p\u003e\n\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003cth\u003eStrategy\u003c\/th\u003e\n    \u003cth\u003eKey Metrics\u003c\/th\u003e\n    \u003cth\u003eImpact\u003c\/th\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eDirect Communication\u003c\/td\u003e\n    \u003ctd\u003e5,000 Providers, 1,200 Representatives\u003c\/td\u003e\n    \u003ctd\u003e15% Increase in Prescriptions (3 Years)\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eCustomer Support\u003c\/td\u003e\n    \u003ctd\u003e85% Satisfaction, \u0026lt;2 min Response\u003c\/td\u003e\n    \u003ctd\u003e¥15 Million Investment\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003ePatient Education\u003c\/td\u003e\n    \u003ctd\u003e10,000 Patients Reached, ¥10 Million Budget\u003c\/td\u003e\n    \u003ctd\u003e70% Improvement in Understanding\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eLong-term Relationships\u003c\/td\u003e\n    \u003ctd\u003e90% Retention Rate, 25% Repeat Prescriptions\u003c\/td\u003e\n    \u003ctd\u003e¥1.2 Billion Sales Contribution\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\u003cbr\u003e\u003ch2\u003eGuilin Sanjin Pharmaceutical Co., Ltd. - Business Model: Channels\u003c\/h2\u003e\n\n\u003cp\u003eGuilin Sanjin Pharmaceutical Co., Ltd. primarily employs several channels to effectively reach and engage its customers in the pharmaceutical sector.\u003c\/p\u003e\n\n\u003ch3\u003eDistribution through pharmacies\u003c\/h3\u003e\n\u003cp\u003eGuilin Sanjin Pharmaceutical utilizes a robust distribution network that includes over \u003cstrong\u003e30,000\u003c\/strong\u003e retail pharmacies across China. In 2022, the company reported that pharmacy sales accounted for approximately \u003cstrong\u003e58%\u003c\/strong\u003e of its total revenue, demonstrating the significance of this channel.\u003c\/p\u003e\n\n\u003ch3\u003eOnline sales platform\u003c\/h3\u003e\n\u003cp\u003eThe shift towards digital platforms has led Guilin Sanjin to enhance its online sales capabilities. As of the end of 2022, online sales represented approximately \u003cstrong\u003e25%\u003c\/strong\u003e of total sales. The company has partnerships with major e-commerce platforms such as JD.com and Alibaba, contributing to a year-on-year growth rate of online sales by \u003cstrong\u003e35%\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ch3\u003ePartnerships with healthcare institutions\u003c\/h3\u003e\n\u003cp\u003eGuilin Sanjin has established strategic partnerships with over \u003cstrong\u003e1,000\u003c\/strong\u003e healthcare institutions. These collaborations have facilitated access to a broader customer base, allowing for the direct supply of pharmaceutical products. In 2023, revenues from institutional sales were reported to be around \u003cstrong\u003e¥1.2 billion\u003c\/strong\u003e, which is approximately \u003cstrong\u003e15%\u003c\/strong\u003e of the company's total revenue.\u003c\/p\u003e\n\n\u003ch3\u003eDirect sales force\u003c\/h3\u003e\n\u003cp\u003eThe company employs a dedicated direct sales force consisting of around \u003cstrong\u003e1,200\u003c\/strong\u003e representatives. This team focuses on building relationships with healthcare providers and promoting product lines directly. In 2022, the direct sales strategy contributed to \u003cstrong\u003e18%\u003c\/strong\u003e of total company sales, highlighting its effectiveness in communicating the value proposition directly to healthcare professionals.\u003c\/p\u003e\n\n\u003ctable\u003e\n    \u003ctr\u003e\n        \u003cth\u003eChannel\u003c\/th\u003e\n        \u003cth\u003ePercentage of Total Revenue\u003c\/th\u003e\n        \u003cth\u003eSales Figures (¥)\u003c\/th\u003e\n        \u003cth\u003eNumber of Partnerships\/Representatives\u003c\/th\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003ePharmacies\u003c\/td\u003e\n        \u003ctd\u003e58%\u003c\/td\u003e\n        \u003ctd\u003e¥3.0 billion\u003c\/td\u003e\n        \u003ctd\u003e30,000+\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eOnline Sales\u003c\/td\u003e\n        \u003ctd\u003e25%\u003c\/td\u003e\n        \u003ctd\u003e¥1.3 billion\u003c\/td\u003e\n        \u003ctd\u003ePartnerships with major platforms\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eHealthcare Institutions\u003c\/td\u003e\n        \u003ctd\u003e15%\u003c\/td\u003e\n        \u003ctd\u003e¥1.2 billion\u003c\/td\u003e\n        \u003ctd\u003e1,000+\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eDirect Sales Force\u003c\/td\u003e\n        \u003ctd\u003e18%\u003c\/td\u003e\n        \u003ctd\u003e¥0.9 billion\u003c\/td\u003e\n        \u003ctd\u003e1,200\u003c\/td\u003e\n    \u003c\/tr\u003e\n\u003c\/table\u003e\n\u003cbr\u003e\u003ch2\u003eGuilin Sanjin Pharmaceutical Co., Ltd. - Business Model: Customer Segments\u003c\/h2\u003e\n\n\u003cp\u003eGuilin Sanjin Pharmaceutical Co., Ltd. targets a variety of customer segments, each defined by specific needs and characteristics.\u003c\/p\u003e\n\n\u003ch3\u003eHealthcare Providers\u003c\/h3\u003e\n\u003cp\u003eHealthcare providers are a significant segment for Guilin Sanjin Pharmaceutical. The company supplies hospitals and clinics with a range of pharmaceutical products, particularly focusing on traditional Chinese medicine (TCM). In 2022, the total revenue from sales to healthcare providers reached approximately \u003cstrong\u003e¥1.5 billion\u003c\/strong\u003e (around \u003cstrong\u003e$230 million\u003c\/strong\u003e), accounting for nearly \u003cstrong\u003e45%\u003c\/strong\u003e of the company’s total revenue.\u003c\/p\u003e\n\n\u003ch3\u003ePatients Seeking Natural Remedies\u003c\/h3\u003e\n\u003cp\u003eThis segment consists of individuals looking for alternative and natural treatment options. The demand for natural products has been increasing; a report from the National Health Commission showed that about \u003cstrong\u003e30%\u003c\/strong\u003e of patients in China prefer TCM as a primary treatment method. Guilin Sanjin has capitalized on this trend, reporting a sales increase of \u003cstrong\u003e20%\u003c\/strong\u003e year-over-year for products targeting this demographic, contributing to revenues of approximately \u003cstrong\u003e¥800 million\u003c\/strong\u003e (about \u003cstrong\u003e$123 million\u003c\/strong\u003e) in 2022.\u003c\/p\u003e\n\n\u003ch3\u003ePharmacies and Retailers\u003c\/h3\u003e\n\u003cp\u003ePharmacies and retail outlets are crucial distribution channels for Guilin Sanjin's products. As of 2022, the company had partnerships with over \u003cstrong\u003e10,000\u003c\/strong\u003e pharmacies across China. Sales through this channel generated approximately \u003cstrong\u003e¥1 billion\u003c\/strong\u003e (around \u003cstrong\u003e$154 million\u003c\/strong\u003e), representing about \u003cstrong\u003e30%\u003c\/strong\u003e of the total revenue. Increasing urbanization and a shift in consumer preferences towards convenience have fueled growth in this segment.\u003c\/p\u003e\n\n\u003ch3\u003eHealth-Conscious Individuals\u003c\/h3\u003e\n\u003cp\u003eThe health-conscious individual segment is rapidly expanding as more consumers prioritize wellness. In 2022, this group contributed roughly \u003cstrong\u003e¥600 million\u003c\/strong\u003e (around \u003cstrong\u003e$92 million\u003c\/strong\u003e) to revenue, marking an increase of \u003cstrong\u003e25%\u003c\/strong\u003e compared to the previous year. A survey conducted by market analysts indicated that around \u003cstrong\u003e75%\u003c\/strong\u003e of urban Chinese adults are actively seeking health supplements, positioning Guilin Sanjin to effectively tailor its product offerings to meet this growing demand.\u003c\/p\u003e\n\n\u003ctable\u003e\n    \u003ctr\u003e\n        \u003cth\u003eCustomer Segment\u003c\/th\u003e\n        \u003cth\u003eRevenue (2022)\u003c\/th\u003e\n        \u003cth\u003ePercentage of Total Revenue\u003c\/th\u003e\n        \u003cth\u003eGrowth Rate\u003c\/th\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eHealthcare Providers\u003c\/td\u003e\n        \u003ctd\u003e¥1.5 billion ($230 million)\u003c\/td\u003e\n        \u003ctd\u003e45%\u003c\/td\u003e\n        \u003ctd\u003e-\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003ePatients Seeking Natural Remedies\u003c\/td\u003e\n        \u003ctd\u003e¥800 million ($123 million)\u003c\/td\u003e\n        \u003ctd\u003e25%\u003c\/td\u003e\n        \u003ctd\u003e20%\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003ePharmacies and Retailers\u003c\/td\u003e\n        \u003ctd\u003e¥1 billion ($154 million)\u003c\/td\u003e\n        \u003ctd\u003e30%\u003c\/td\u003e\n        \u003ctd\u003e-\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eHealth-Conscious Individuals\u003c\/td\u003e\n        \u003ctd\u003e¥600 million ($92 million)\u003c\/td\u003e\n        \u003ctd\u003e18%\u003c\/td\u003e\n        \u003ctd\u003e25%\u003c\/td\u003e\n    \u003c\/tr\u003e\n\u003c\/table\u003e\n\u003cbr\u003e\u003ch2\u003eGuilin Sanjin Pharmaceutical Co., Ltd. - Business Model: Cost Structure\u003c\/h2\u003e\n\n\u003ch3\u003eR\u0026amp;D Expenses\u003c\/h3\u003e\n\u003cp\u003eFor the fiscal year 2022, Guilin Sanjin Pharmaceutical Co., Ltd. reported Research and Development (R\u0026amp;D) expenses of approximately \u003cstrong\u003eRMB 200 million\u003c\/strong\u003e. This represents about \u003cstrong\u003e10%\u003c\/strong\u003e of their total revenue, which was around \u003cstrong\u003eRMB 2 billion\u003c\/strong\u003e. The company prioritizes innovation and development of new drug formulations, with several ongoing projects aimed at expanding their product portfolio.\u003c\/p\u003e\n\n\u003ch3\u003eManufacturing Costs\u003c\/h3\u003e\n\u003cp\u003eThe manufacturing costs for Guilin Sanjin were estimated at \u003cstrong\u003eRMB 800 million\u003c\/strong\u003e in 2022, accounting for approximately \u003cstrong\u003e40%\u003c\/strong\u003e of total expenses. This includes costs associated with raw materials, labor, and overhead associated with their production facilities. The company operates several manufacturing plants, and the efficiency of these plants significantly impacts their overall cost structure.\u003c\/p\u003e\n\n\u003ch3\u003eMarketing and Sales Costs\u003c\/h3\u003e\n\u003cp\u003eIn 2022, Guilin Sanjin invested around \u003cstrong\u003eRMB 300 million\u003c\/strong\u003e in marketing and sales efforts, which constituted about \u003cstrong\u003e15%\u003c\/strong\u003e of their total revenue. This expenditure includes promotional activities, sales force expenses, and expenses related to market research. The company aims to enhance its market presence, especially in emerging markets.\u003c\/p\u003e\n\n\u003ch3\u003eRegulatory Compliance Fees\u003c\/h3\u003e\n\u003cp\u003eRegulatory compliance fees and related expenses were reported to be around \u003cstrong\u003eRMB 100 million\u003c\/strong\u003e in 2022. These costs cover compliance with local and international regulations for pharmaceuticals, licensing fees, and the costs associated with quality assurance processes. This represents around \u003cstrong\u003e5%\u003c\/strong\u003e of the company's overall expenditures.\u003c\/p\u003e\n\n\u003ctable\u003e\n    \u003ctr\u003e\n        \u003cth\u003eCost Category\u003c\/th\u003e\n        \u003cth\u003e2022 Expenses (RMB)\u003c\/th\u003e\n        \u003cth\u003ePercentage of Total Revenue (%)\u003c\/th\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eR\u0026amp;D Expenses\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e200 million\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e10%\u003c\/strong\u003e\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eManufacturing Costs\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e800 million\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e40%\u003c\/strong\u003e\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eMarketing and Sales Costs\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e300 million\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e15%\u003c\/strong\u003e\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eRegulatory Compliance Fees\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e100 million\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e5%\u003c\/strong\u003e\u003c\/td\u003e\n    \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eOverall, Guilin Sanjin Pharmaceutical Co., Ltd.'s cost structure reflects a strategic focus on both R\u0026amp;D and operational efficiency, aiming to balance innovation with sustainable growth in the competitive pharmaceutical landscape.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eGuilin Sanjin Pharmaceutical Co., Ltd. - Business Model: Revenue Streams\u003c\/h2\u003e\n\n\u003cp\u003eGuilin Sanjin Pharmaceutical Co., Ltd. generates revenue through diverse channels, reflecting its strategic approach to market engagement. Below is a detailed breakdown of the revenue streams:\u003c\/p\u003e\n\n\u003ch3\u003eSales of Herbal Medicines\u003c\/h3\u003e\n\u003cp\u003eThe primary revenue stream for Guilin Sanjin Pharmaceutical comes from the sales of herbal medicines. In 2022, the company reported total revenue of approximately \u003cstrong\u003eRMB 1.76 billion\u003c\/strong\u003e, with herbal medicines contributing significantly to this figure. The herbal medicine segment alone accounted for about \u003cstrong\u003e74%\u003c\/strong\u003e of the total revenue, showcasing its dominance in the company's offerings.\u003c\/p\u003e\n\n\u003ch3\u003eLicensing and Partnerships\u003c\/h3\u003e\n\u003cp\u003eLicensing agreements and partnerships form another crucial part of the revenue model. Guilin Sanjin has strategically aligned with various domestic and international partners to leverage its intellectual property. For instance, in 2021, the company earned \u003cstrong\u003eRMB 120 million\u003c\/strong\u003e through licensing agreements, primarily from royalties on herbal formulations. This represented a growth of \u003cstrong\u003e15%\u003c\/strong\u003e compared to the previous fiscal year.\u003c\/p\u003e\n\n\u003ch3\u003eOnline Sales\u003c\/h3\u003e\n\u003cp\u003eWith the increasing trend towards e-commerce, Guilin Sanjin has developed a robust online sales platform. In 2022, online sales reached approximately \u003cstrong\u003eRMB 300 million\u003c\/strong\u003e, accounting for about \u003cstrong\u003e17%\u003c\/strong\u003e of total sales. This channel has seen a year-on-year growth rate of \u003cstrong\u003e30%\u003c\/strong\u003e, reflecting the shift in consumer purchasing behavior toward digital platforms. The online segment is expected to continue expanding as the company enhances its digital marketing efforts.\u003c\/p\u003e\n\n\u003ch3\u003eExport Revenues\u003c\/h3\u003e\n\u003cp\u003eExport revenues also play a significant role in Guilin Sanjin's business model. The company exports its products to over \u003cstrong\u003e20 countries\u003c\/strong\u003e, with export sales contributing to nearly \u003cstrong\u003e9%\u003c\/strong\u003e of total revenues. In 2022, export revenues were recorded at approximately \u003cstrong\u003eRMB 150 million\u003c\/strong\u003e, with a compound annual growth rate (CAGR) of \u003cstrong\u003e12%\u003c\/strong\u003e over the past three years. The key markets include Southeast Asia and Europe, where demand for herbal medicine is increasing.\u003c\/p\u003e\n\n\u003ctable\u003e\n    \u003ctr\u003e\n        \u003cth\u003eRevenue Stream\u003c\/th\u003e\n        \u003cth\u003e2022 Revenue (RMB million)\u003c\/th\u003e\n        \u003cth\u003ePercentage of Total Revenue\u003c\/th\u003e\n        \u003cth\u003eYear-on-Year Growth (%)\u003c\/th\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eHerbal Medicines\u003c\/td\u003e\n        \u003ctd\u003e1300\u003c\/td\u003e\n        \u003ctd\u003e74%\u003c\/td\u003e\n        \u003ctd\u003e8%\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eLicensing and Partnerships\u003c\/td\u003e\n        \u003ctd\u003e120\u003c\/td\u003e\n        \u003ctd\u003e7%\u003c\/td\u003e\n        \u003ctd\u003e15%\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eOnline Sales\u003c\/td\u003e\n        \u003ctd\u003e300\u003c\/td\u003e\n        \u003ctd\u003e17%\u003c\/td\u003e\n        \u003ctd\u003e30%\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eExport Revenues\u003c\/td\u003e\n        \u003ctd\u003e150\u003c\/td\u003e\n        \u003ctd\u003e9%\u003c\/td\u003e\n        \u003ctd\u003e12%\u003c\/td\u003e\n    \u003c\/tr\u003e\n\u003c\/table\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45658835910805,"sku":"002275sz-business-model-canvas","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/002275sz-business-model-canvas.png?v=1739107655","url":"https:\/\/dcf-model.com\/products\/002275sz-business-model-canvas","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}